An aggregate number of 29,200 new shares of Herantis Pharma Plc (“Herantis“) have been subscribed for with option rights under the option programs 2010 and 2014. The new shares have been registered with the trade register maintained by the Finnish Patent and Registration Office today. The new shares will confer shareholder rights in Herantis after they have been issued in the book-entry system, on or about 19 July 2023.

Trading with the new shares is expected to commence on the Nasdaq First North Growth Market Finland marketplace on or about 20 July 2023, provided that Nasdaq Helsinki Ltd approves the listing application submitted by Herantis.

As a result of the share subscriptions, the total number of shares in Herantis will increase to 16,941,594.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel.: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: [email protected]

———————————

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

You can read the rest of the article here.